Overview of the GBPP 2025 Participant Industry Mix
More than 200 Korean bio and pharmaceutical companies are taking part in the GBPP 2025 Global Biopharma Plaza. This review breaks the participant pool into five segments to assess the current landscape in greater detail: biosimilars, active pharmaceutical ingredients (APIs), finished drugs, CMO/CDMO, and medical devices and diagnostics.
By evaluating the Bangladesh market fit of each segment, this article proposes a practical priority map for Korean companies considering entry into the country. Korea's competitive advantage is most visible in biosimilars and CMO/CDMO services.
Biosimilars Segment (35%)
Biosimilars account for the largest share of GBPP participants, representing 35% of the total or 70 companies. Korea is a leading force in the global biosimilar market, backed by firms such as Celltrion and Korea Corp Bioepis, with broad pipelines covering monoclonal antibodies such as trastuzumab and infliximab, as well as insulin and growth hormone products.
| Sub-Segment | No. of Firms | Share | Key Products | Bangladesh Fit |
|---|---|---|---|---|
| Antibody Biosimilars | 30 firms | 43% | Trastuzumab, Adalimumab | Medium (price barrier) |
| Insulin and Hormones | 20 firms | 29% | Insulin, growth hormone | High (strong demand) |
| Bio CDMO | 12 firms | 17% | Cell lines, culture process | Medium (tech transfer) |
| Bio Materials | 8 firms | 11% | Media, reagents, filters | Low (limited local demand) |
API and CMO/CDMO Segments
Within the API segment, Bangladesh shows the strongest fit for antibiotic inputs such as cephalosporin and amoxicillin, as well as analgesic and antipyretic ingredients such as paracetamol and ibuprofen. Even though Bangladeshi pharmaceutical firms supply 97% of domestic demand, the country still depends on imports for more than 60% of its high-quality APIs. Korean APIs are recognized for a quality premium relative to Indian and Chinese products.
Medical Devices, Diagnostics, and Finished Drugs
| Segment | Market Size | Import Dependence | Korean Competitiveness | Fit | Priority |
|---|---|---|---|---|---|
| API antibiotics and antipyretics | $800M | 60%+ | Quality advantage | ★★★★★ | Top priority |
| Medical devices and diagnostics | $400M | 85% | Technology advantage | ★★★★★ | Top priority |
| CMO/CDMO | $200M | Growing | Extensive experience | ★★★★☆ | Second priority |
| Insulin and biosimilars | $300M | 40% | Global leadership | ★★★★☆ | Second priority |
| Finished drugs | $2.5B | 3% | Moderate | ★★★☆☆ | Third priority |
| Bio materials | $50M | 90% | High quality | ★★★☆☆ | Third priority |
Bangladesh Market Entry Strategy
The participant industry mix at GBPP 2025 shows that Korean bio and pharmaceutical exporters hold capabilities across the full value chain, from biosimilars to APIs, CMO services, and medical devices. In the Bangladesh market, API antibiotics and antipyretic materials, along with medical devices and diagnostics, stand out as the most immediately actionable segments. CMO/CDMO services and insulin biosimilars represent the next wave of medium-term growth opportunities. A structured roadmap that carries buyer relationships from GBPP into DGDA registration, sample supply, and commercial partnership agreements will be essential.